Current Atherosclerosis Reports

, Volume 11, Issue 5, pp 323–325

Statin therapy, inflammation, and risk for cardiovascular events: The light from JUPITER is illuminating

Clinical Trials Report
  • 26 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115–126.PubMedCrossRefGoogle Scholar
  2. 2.
    Libby P: What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001, 88:3J–6J.PubMedGoogle Scholar
  3. 3.
    Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868–874.PubMedCrossRefGoogle Scholar
  4. 4.
    Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365–372.PubMedGoogle Scholar
  5. 5.
    Ridker PM, Bassuk SS, Toth PP: C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep 2003, 5:341–349.PubMedCrossRefGoogle Scholar
  6. 6.
    Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.PubMedCrossRefGoogle Scholar
  7. 7.
    Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003, 107:391–397.PubMedCrossRefGoogle Scholar
  8. 8.
    Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.PubMedCrossRefGoogle Scholar
  9. 9.
    Ridker PM: Clinical usefulness of very high and very low levels of c-reactive protein across the full range of Framingham risk scores. Circulation 2004, 109:1955–1959.PubMedCrossRefGoogle Scholar
  10. 10.
    Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007, 49:2129–2138.PubMedCrossRefGoogle Scholar
  11. 11.
    Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611–619.PubMedCrossRefGoogle Scholar
  12. 12.
    Ridker PM, Morrow DA, Rose LM, et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45:1644–1648.PubMedCrossRefGoogle Scholar
  13. 13.
    Morrow DA, de Lemos JA, Sabatine MS, et al.: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006, 114:281–288.PubMedCrossRefGoogle Scholar
  14. 14.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29–38.PubMedCrossRefGoogle Scholar
  15. 15.
    Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959–1965.PubMedCrossRefGoogle Scholar
  16. 16.
    Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Sterling Rock Falls ClinicSterlingUSA
  2. 2.SterlingUSA

Personalised recommendations